Literature DB >> 1733446

Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining.

H P Henneberry1, G W Aherne.   

Abstract

In previous pharmacologic studies, the native fluorescent properties of doxorubicin (DOX) have been utilised to visualise tissue and cellular drug distribution. Such distribution studies provide valuable additional information to that obtained by measuring tissue drug concentration alone. An alternative immunocytochemical method of drug localisation using a rabbit immunoadsorbed antiserum to DOX and silver-enhanced gold-labelled second antibodies has been used to achieve visualisation of DOX in normal and malignant tissues from drug-treated animals and patients, and in human tumour cell lines treated in vitro. Non-specific staining in untreated tissues or in controls stained without primary antibody was minimal. Widespread dark brown to black specific immunostaining was observed in the normal tissues of drug-treated animals and in rat sarcoma and in the mouse EMT6 mammary tumour. In human breast tumour biopsy samples obtained at surgery 1 h following a 25 mg intravenous dose of DOX, considerable variation in drug distribution was observed which appeared to be related to drug concentration. Both nuclear and membrane staining was apparent; the latter was especially noticeable in human tumour cells grown in the presence of DOX at concentrations greater than 0.92 microM. Immunolocalisation using silver enhanced gold-labelled reagents provides an additional technique to study cell and organ specific differences in drug uptake and distribution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733446      PMCID: PMC1977343          DOI: 10.1038/bjc.1992.15

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  The immunogold-silver staining method. A powerful tool in histopathology.

Authors:  G W Hacker; D R Springall; S Van Noorden; A E Bishop; L Grimelius; J M Polak
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 2.  DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy.

Authors:  B S Glisson; W E Ross
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

3.  An immunocolloid method for the electron microscope.

Authors:  W P Faulk; G M Taylor
Journal:  Immunochemistry       Date:  1971-11

4.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

Review 5.  Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.

Authors:  R J Cersosimo; W K Hong
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

6.  Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.

Authors:  S E Salmon; T M Grogan; T Miller; R Scheper; W S Dalton
Journal:  J Natl Cancer Inst       Date:  1989-05-03       Impact factor: 13.506

7.  Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.

Authors:  A A Hindenburg; J E Gervasoni; S Krishna; V J Stewart; M Rosado; J Lutzky; K Bhalla; M A Baker; R N Taub
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

8.  Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue.

Authors:  R Danesi; A Paparelli; N Bernardini; M Del Tacca
Journal:  Eur J Cancer Clin Oncol       Date:  1988-07

9.  Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography.

Authors:  S Shinozawa; Y Mimaki; Y Araki; T Oda
Journal:  J Chromatogr       Date:  1980-08-29

10.  Evaluation of a commercially available radioimmunoassay kit for measurement of doxorubicin in plasma.

Authors:  E Piall; G W Aherne; V Marks
Journal:  Clin Chem       Date:  1982-01       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.